TLP
MRTX

Tri Locum Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Tri Locum Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-24,201
Closed -$874K – 90
2023
Q2 		$874K Buy
+24,201
New +$997K 0.33% 39
2023
Q1 		– Sell
-104,598
Closed -$4.74M – 92
2022
Q4 		$4.74M Sell
104,598
-46,936
-31% -$3.04M 1.92% 20
2022
Q3 		$10.6M Buy
+151,534
New +$11.2M 2.9% 14

Other funds holding MRTX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tri Locum Partners's MRTX Position: Q3 2023 in Review

Tri Locum Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 24,201 shares — an estimated $874K sold.

Tri Locum Partners first reported a position in MRTX in Q3 2022 and held it in 3 quarters. The position peaked at $10.6M in Q3 2022. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Tri Locum Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Tri Locum Partners sold 24,201 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $874K.
  • Tri Locum Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Tri Locum Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $10.6M in Q3 2022.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Tri Locum Partners's 13F filing for Q3 2023, filed 14 Nov 2023.